a selling opportunity, page-2

1) the only reason for the price jump is because TIS was mentioned in the ASI.

Not likely - ASI have been talking about TIS with same enthusiasm for at least 6 months.

2) if you read carefully you will realize that the latest trial results are not as good as the previous ones.

Not so. Should compare like with like. Canadian trials were diabetic ulcers. Previous trials were venous ulcers. Diabetic ulcers typically have smaller surface areas but are rather deeper than venous - latest trials show excellent reduction in overall volume of these ulcers - comparable with the earlier Fremantle study. AND - as the ASI report mentioned, the new formulation of VitroGro is showing superior healing than its predecessor.

3) Only enough cash left till end of this year (se ann.) so expect more dilution.

This is not news - purpose of the last raising was to get through phase3 trials which looks like being comfortably achieved.

Don't know anything about the "promised cash resource".

My opinions only - dyor